Decoding the future of healthcare
Key points to remember
- Recent breakthroughs in genomics are helping advance the next generation of breakthroughs in medicine.
- Gene therapies could transform the healthcare industry and become a $36 billion market by 2027.1
- Megatrend ETFs can help capture potential medical breakthroughs and keep investors diversified across many stocks.
Earlier this month, the Biden-Harris administration announced the reinstatement of the Cancer Moonshot program – aimed at reducing the cancer death rate by at least 50% over the next 25 years.2. The program will bring about improvements in cancer diagnosis and prevention, much of which is driven by new tools such as mRNA technology. The program will also help accelerate the clinical trial processes for bringing these therapies to market, enabling potentially earlier than expected commercialization for many cancer drugs, presenting potential growth opportunities for investors.
The pandemic has demonstrated how drugmakers can quickly and efficiently harness medical innovations. The mRNA technology used in vaccines to fight COVID-19 is being studied for potential deployment against rabies, influenza, Zika, HIV and cancer.3
For investors, breakthroughs in modern medicine could represent potential long-term growth opportunities. Consider that the gene therapy market is expected to grow 34% annually, to $36 billion, by 2027.4 The US Food and Drug Administration estimates that by 2025 it will approve between 10 and 20 cell and gene therapy products per year.5
CRISPR-Cas9: a copy-paste job
Source: BlackRock Clinic and Mayo. For illustrative purposes only.
Large-scale genetic sequencing
Advances in genetic sequencing underpin many advances in the life sciences, and sequencing millions of DNA codes has become cheaper and easier.
Over the past two decades, the cost of genetic sequencing has fallen more than 100-fold – from $100,000 in 2001 to less than $1,000 in 2020 – enabling scalable scientific use and paving the way for new generation of personalized therapies, particularly in areas such as oncology.6
Sequencing costs ($) per human genome
Source: National Institute for Human Genome Research, “DNA sequencing costs: data», August 2020.
A revolutionary gene-editing technology is the CRISPR-Cas9 system. This technology allows researchers to isolate and manipulate parts of human DNA with “defects”. CRISPR-Cas9 consists of two components: a guide RNA, which can locate and recognize the DNA sequence to be edited, and the Cas9 protein, which can cut out the part of the DNA that is defective. A guide RNA and a Cas9 protein work together like Clippy, the Microsoft Word desktop program’s signature digital assistant, locating and deleting faulty parts of the gene and replacing them with the correct ones.
The falling costs of genetic sequencing technology, combined with the successful application of gene editing, are bringing potential cures to these diseases much faster and cheaper than the latest generation of drug discovery.
Given the remarkable groundbreaking results of genomics research, investors may consider a megatrends approach to investing in targeted themes like genomics. Index megatrend tracking ETFs can help capture the potential of medical breakthroughs, while continuing to diversify among the many companies that are poised to potentially benefit from the growth of the theme.
Advances in the biological sciences through the use of computing, data, and artificial intelligence are opening new doors in healthcare that can provide more precise therapies for a wide range of diseases.
1 GlobalNewsWire,”The gene therapy market is worth $35.67 billion at a CAGR of 33.6%», August 2020.
2 White House, “Fact Sheet: President Biden Reigniting Cancer Moonshot to End Cancer As We Know It.” February 2022
3 Yale School of Public Health, “The Application and Future Potential of mRNA Vaccines,” May 7, 2021.
4 GlobalNewsWire,”The gene therapy market is worth $35.67 billion at a CAGR of 33.6%», August 2020.
5 Statement by Scott Gottlieb, MD, Former Food and Drug Commissioner, Food and Drug Administration (January 15, 2019).
6 National Institute for Human Genome Research,DNA sequencing costs: data», August 2020.
Carefully consider the Funds’ investment objectives, risk factors and charges and expenses before investing. This and other information can be found in the prospectuses of the Funds or, if available, in the simplified prospectuses, which can be obtained by visiting the prospectus pages of the iShares Funds and BlackRock Fund. Read the prospectus carefully before investing.
Investing involves risk, including possible loss of principal.
International investing involves risks, including foreign currency risk, limited liquidity, less government regulation and the possibility of significant volatility due to adverse political, economic or other developments. These risks are often heightened for investments in emerging/developing markets or in concentrations of individual countries.
Funds that focus their investments in specific industries, sectors, markets or asset classes may underperform or be more volatile than other industries, sectors, markets or asset classes and the general securities market.
Technologies perceived as supplanting older technologies or creating new markets may not actually do so. Companies that initially develop new technology may not be able to capitalize on the technology.
This document represents an assessment of the market environment as of the date indicated; is subject to change; and is not intended to be a prediction of future events or a guarantee of future results. This information should not be considered by the reader as research or investment advice regarding the funds or any particular issuer or security.
The strategies discussed are strictly for illustrative and educational purposes and do not constitute a recommendation, offer or solicitation to buy or sell securities or to adopt any investment strategy. There is no guarantee that the strategies discussed will be effective.
The information presented does not take into account commissions, tax implications or other transaction costs, which may significantly affect the economic consequences of a given investment strategy or decision.
This material contains general information only and does not take into account any individual’s financial situation. This information should not be relied upon as the primary basis for an investment decision. Rather, one should assess whether the information is appropriate in the individual circumstances and consider speaking to a financial professional before making an investment decision.
The information provided is not intended to be tax advice. Investors should be advised to consult their tax or finance professionals for further information regarding their specific tax situation.
The Funds are distributed by BlackRock Investments, LLC (together with its affiliates, “BlackRock”).
The iShares Funds are not sponsored, endorsed, issued, sold or promoted by Bloomberg, BlackRock Index Services, LLC, Cohen & Steers, European Public Real Estate Association (“EPRA®”), FTSE International Limited (“FTSE”), ICE Data Indices, LLC, NSE Indices Ltd, JPMorgan, JPX Group, London Stock Exchange Group (“LSEG”), MSCI Inc., Markit Indices Limited, Morningstar, Inc., Nasdaq, Inc., National Association of Real Estate Investment Trusts ( “NAREIT”), Nikkei, Inc., Russell or S&P Dow Jones Indices LLC. None of these companies makes any representation regarding the advisability of investing in the Funds. Except for BlackRock Index Services, LLC, which is an affiliate, BlackRock Investments, LLC is not affiliated with any of the companies listed above.
Neither FTSE, LSEG nor NAREIT makes any representations about the FTSE Nareit Equity REITS Index, the FTSE Nareit All Residential Capped Index or the FTSE Nareit All Mortgage Capped Index. Neither FTSE, EPRA, LSEG nor NAREIT make any representations about the FTSE EPRA Nareit Developed ex-US Index or the FTSE EPRA Nareit Global REITs Index. “FTSE®” is a registered trade mark of the companies of the London Stock Exchange Group and is used by FTSE under licence.
© 2022 BlackRock, Inc. All rights reserved. BLACKROCK, BLACKROCK SOLUTIONS, BUILD ON BLACKROCK, ALADDIN, iSHARES, iBONDS, FACTORSELECT, iTHINKING, iSHARES CONNECT, FUND FRENZY, LIFEPATH, WHAT TO DO WITH MY MONEY, INVESTING FOR A NEW WORLD, BUILT FOR THESE TIMES, the iShares Core chart, CoRI and the CoRI logo are trademarks of BlackRock, Inc. or its subsidiaries in the United States and elsewhere. All other trademarks are the property of their respective owners.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.